# StrataGraft® Skin Tissue Expanded Access at Specific Study Sites ( StrataCAT )

> **NCT04123548** · PHASE3 · COMPLETED · sponsor: **Stratatech, a Mallinckrodt Company** · enrollment: 52 (actual)

## Conditions studied

- Deep Partial-thickness Burn

## Interventions

- **BIOLOGICAL:** StrataGraft skin tissue

## Key facts

- **NCT ID:** NCT04123548
- **Lead sponsor:** Stratatech, a Mallinckrodt Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-02-18
- **Primary completion:** 2022-01-26
- **Final completion:** 2022-01-26
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2023-11-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04123548

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04123548, "StrataGraft® Skin Tissue Expanded Access at Specific Study Sites ( StrataCAT )". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04123548. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*